Wouter Nijkamp

The Netherlands Cancer Institute — Netherlands

Medicine · Health Sciences

10h-index2.6kcitations45works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Peptidase Inhibition and Analysis(17), PI3K/AKT/mTOR signaling in cancer(14), Chronic Lymphocytic Leukemia Research(12), Chronic Myeloid Leukemia Treatments(11), Signaling Pathways in Disease(10)

Publications45 total

Supplemental Table S2 and Table S3 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S1 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Table S1 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental figure legends from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S5 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S2 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S4 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Table S1 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental figure legends from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S3 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S4 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S3 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S5 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S1 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Data from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Table S2 and Table S3 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplemental Figure S2 from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Data from Loss of <i>ARID1A</i> Activates <i>ANXA1</i>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
2023Open Access
Supplementary Figure 3 from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
2023Open Access
Supplementary Figure 3 from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Roderick L. Beijersbergen(43), René Bernards(40), Theo Knijnenburg(22), Lodewyk F.A. Wessels(22), Katrien Berns(20), E. Marielle Hijmans(20), Amir Sonnenblick(19), Annemiek M.C. Gennissen(19), Sylvain Brohée(19), Bastiaan Evers(19), Debora Fumagalli(19), Christine Desmedt(19), Sibylle Loibl(19), Carsten Denkert(19), Patrick Neven(19), Tjalling Bosse(19), Michiel S. van der Heijden(19), Sanne Hindriksen(19), Heikki Joensuu(19), Gordon B. Mills(19)